Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non-ccRCC
NCT07488533Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, fruquintinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Sun Yat-sen University. Started Aug 2025; status: active, not recruiting.
02
Drugs
serplulimabfruquintinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT07488533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488533.